Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity

다국어 초록 (Multilingual Abstract)

Purpose: Anthracycline can effectively treat hematologic malignancies, but has significant risk of cardiotoxicity. We measured the clinical correlation between brain natriuretic peptide (BNP) and anthracycline-induced cardiotoxicity.

Materials and Methods: Between March 2005 and March 2007, 86 patients with acute leukemia, malignant lymphoma, or multiple myeloma receiving systemic chemotherapy with anthracycline were enrolled in the Department of Hemato-oncology, Kosin University Gospel Hospital. We investigated the relationship between BNP level and cardiotoxicity through echocardiography, electrocardiography, BNP levels, and symptoms of heart failure at each chemotherapy cycle.

Results: Of the 86 participants (mean age, 48.5 years; range 20∼65 years), cardiotoxicity developed in 21 patients (24.4%), with 2 patients showing arrhythmia only, 17 patients with transient aspects of heart failure, and 2 patients with chronic heart failure. Cardiotoxicity related to serum BNP level, age, cumulative dose of anthracycline, accompanying chronic disease, and elevated level of troponin-I. Heart failure was more common if BNP levels reached 100 pg/ml at least once.

Conclusions: The clinical correlation between BNP and cardiotoxicity was significant in patients with systemic anthracycline chemotherapy. A prospective clinical trial will be needed to identify the causal relationship between serum BNP level and cardiotoxicity.

참고문헌 (Reference)

1 Maisel AS, "Utility of B-natriuretic peptide as a rapid,point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction" 141 : 367-74, 2001

2 Herman EH, "Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity" 58 : 195-7, 1998

3 McKee PA, "The natural history of congestive heart failure: the Framingham study" 285 : 1441-6, 1971

4 Hequet O., "Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults" 22 : 1864-71, 2004

5 Von Hoff DD, "Risk factors for doxorubicin-induced congestive heart failure" 91 : 710-7, 1979

6 Ganz WI, "Review of tests for monitoring doxorubicin-induced cardiomyopathy" 53 : 461-70, 1996

7 Ewer MS, "Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment" 23 : 7820-6, 2005

8 Nysom K., "Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia" 16 : 545-50, 1998

9 Batist G., "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer" 19 : 1444-54, 2001

10 Speyer JL, "Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer" 319 : 745-52, 1988

11 Hayakawa H., "Plasma levels of natriuretic peptides in relation to doxorubicin- induced cardiotoxicity and cardiac function in children with cancer" 37 : 4-9, 2001

12 Nousiainen T., "Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients" 101 : 601-7, 2001

13 Nousiainen T., "Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma" 62 : 135-41, 1999

14 Poutanen T., "Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children" 21 : 2349-56, 2003

15 Bonneterre J., "Long-term cardiac follow-up in relapse- free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group" 22 : 3070-9, 2004

16 Cardinale D., "Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy" 36 : 517-22, 2000

17 Hale ER, "Latent injury after the double-edged sword of chemo/radiation. In: 2005 ASCO educational book, Alexandria" 739-46, 2005

18 Lipshultz SE, "Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer" 332 : 1738-43, 1995

19 Bristow MR, "Early anthracycline cardiotoxicity" 65 : 823-32, 1978

20 Swain SM, "Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy" 15 : 1333-40, 1997

21 Lipshultz SE, "Cardiovascular trials in long-term survivors of childhood cancer" 22 : 769-73, 2004

22 Ewer M., "Cardiotoxicity of chemotherapeutic drugs. In: Perry MC, editor. The chemotherapy sourcebook" Williams & Wilkins 458-68, 2001

23 Floyd JD, "Cardiotoxicity of cancer therapy" 23 : 7685-96, 2005

24 Steinherz LJ, "Cardiac toxicity in:Cancer: principles and practice of oncology" Williams & Wilkins 2904-21, 2001

25 Theodoulou M., "Cardiac effects of adjuvant therapy for early breast cancer" 30 : 730-9, 2003